We describe a multichannel heterogeneous immunoassay analyzer in which a sample is split between disposable reaction trays in a group of linear tracks. The system's pipettor uses noninvasive sensing of the sample volume and disposable pipet tips. Each assay track has (a) a conveyor belt for moving reaction trays to predetermined functional stations, (b) temperature-controlled tunnels, (C) noncontact transfer of the reaction mixture between incubation and detection wells, and (c singlephoton counting to detect a chemiluminescence (CL) signal from the captured immunochemical product. A novel disposable reaction tray, with separate reaction and detection wells and self-contained fluid removal, is used in conjunction with the transfer device on the track to produce a carryover-free system. The linear immunoassay track has nine predetermined positionsfor performing individualassay steps. Assay step sequence and timing is selected by changing the location of the assay modules between these predetermined positions.The assay methodology, a combination of microparticlecapture and direct detection of a CL signal on a porous matrix, offers excellent sensitivity, specificity, and ease of automation. Immunoassay configurations have been tested for hepatitis B surface antigen and for antibodies to hepatitis B core antigen, hepatitis C virus, human immunodeficiency virus I and II, and human T-cell leukemia virus I and II. To accomplish the throughput goal, we used the following strategies: (a) short assay incubation times through use of microparticles as the capture phase in the immunoassay, (b) large instrument sample capacity (168 samples for early versions and 308 for production instruments), and (c) parallel sample processing, sothat immunoassay tests for as many as six infectious diseases per sample could be performed simultaneously; alternatively, up to 11 combined virology and bloodtyping tests can be simultaneously performed on the samples. To accomplish a carryover-free system, we used disposable pipet tips, noninvasive sensing of the liquid level of the sample, and a noncontact method for transferring the reaction mixture. The sensitivity and specificity goal was achieved by using chemilwninescence (CL) detection, using separate sample-incubation and signal-detection wells, and tightly controlling the temperature over the duration of the assay.
We describe a multichannel heterogeneous immunoassay analyzer in which a sample is split between disposable reaction trays in a group of linear tracks. The system's pipettor uses noninvasive sensing of the sample volume and disposable pipet tips. Each assay track has (a) a conveyor belt for moving reaction trays to predetermined functional stations, (b) temperature-controlled tunnels, (C) noncontact transfer of the reaction mixture between incubation and detection wells, and (c singlephoton counting to detect a chemiluminescence (CL) signal from the captured immunochemical product. A novel disposable reaction tray, with separate reaction and detection wells and self-contained fluid removal, is used in conjunction with the transfer device on the track to produce a carryover-free system. The linear immunoassay track has nine predetermined positionsfor performing individualassay steps. Assay step sequence and timing is selected by changing the location of the assay modules between these predetermined positions.The assay methodology, a combination of microparticlecapture and direct detection of a CL signal on a porous matrix, offers excellent sensitivity, specificity, and ease of automation. Immunoassay configurations have been tested for hepatitis B surface antigen and for antibodies to hepatitis B core antigen, hepatitis C virus, human immunodeficiency virus I and II, and human T-cell leukemia virus I and II. The goals of our work were to (a) build a highthroughput immunoassay screening analyzer for blood banks and high-volume laboratories; (b) construct a carryover-free system to avoid possible false-positive results and hence unnecessary retesting; and (c) achieve sensitivities and specificities equal or superior to those of current enzyme immunoassay methods.
To accomplish the throughput goal, we used the following strategies: (a) short assay incubation times through use of microparticles as the capture phase in the immunoassay, (b) large instrument sample capacity (168 samples for early versions and 308 for production instruments), and (c) parallel sample processing, sothat immunoassay tests for as many as six infectious diseases per sample could be performed simultaneously; alternatively, up to 11 combined virology and bloodtyping tests can be simultaneously performed on the samples. To accomplish a carryover-free system, we used disposable pipet tips, noninvasive sensing of the liquid level of the sample, and a noncontact method for transferring the reaction mixture. The sensitivity and specificity goal was achieved by using chemilwninescence (CL) detection, using separate sample-incubation and signal-detection wells, and tightly controlling the temperature over the duration of the assay.
The instrument we developed to implement these strategies comprised an automated pipettor; a staging area for samples, controls, and disposables; parallel chemiluminescence immunoassay (CLIA) processing channels; a solid-waste disposal receptacle; and a controlling computer. Here we describe the researchlclinical instruments and present the data generated with these systems. The production units (data not included) have enhanced operator interaction, refrigerated reagent storage, computer data tracking and diagnostics, and enhanced graphics, but have the same assay performance and throughput. Subsequent instruments also include up to two blood-typing channels, where agglutinates are detected in microtiter plate wells through photometric detection; these instruments have the capability for photometric determination of alanine aminotransferase and for screening for syphilis.
Because the system is primarily designed for donor #{149} noembryomc antigen (CEA). This analyzer can measure both short-lived acridinium-labeled CL and long-lived alkaline phosphatase-catalyzed dioxetane CL. The right-hand side of the reaction tray is designatedA, the left-hand side is B 2 is a plot of the pressure difference for a series of consecutive pressure readings as the pipet tip is moved toward the sample, touches the surface, and is then moved away from the sample. Each independent z-axis motion is then stopped and the pipettor is stepped into the sample while the sample is aspirated. The step and aspiration rates are controlled to keep the tip immersed in the fluid at the same depth throughout.
Materials and Methods

Instrumentation
Aspiration is performed in 100-.tL increments. The pressure difference is measured after each aspiration step and compared with a range of expected pressures. Readings falling within this pressure window veri1r a normal sample aspiration ( Figure 3, top) ; pressure readings falling outside the predetermined window indicate a heterogeneity in the sample. For example, a smaller pressure difference indicates the presence of bubbles ( Figure 3, middle) ; a larger pressure difference indicates the presenceof clots or indicates that the plasma volume is insufficient, such that the pipet tip has reached the packed cells layer (Figure 3, bottom) . In either instance, aspiration of the sample is stopped, and the sample condition is flagged. Processing of this sample along the channel is discontinued.
A volume of sample larger than the total required for all the assays is aspirated into the pipet tip. The pipettor moves upward to clear the sample tube and then moves across the installed channels to dispense the appropriate volume into each channel. At the end of the pipetting cycle, the pipettor moves to the tip-removal station, where tips are removed and discarded. For instruments equipped with a blood-typing channel (agglutination channels), the pipettor moves to this channel to dispense plasma into defined wells of a microtiter plate, then returns to the same samples to pick up erythrocytes to be pipetted for reverse typing.
Samples and controls: Samples in 13 x 100 mm and 16 x 100 mm blood-collection tubes are accepted in tube During this period, the tray remains in position so that an assay step can be performed. and anti-HCV are performed in three steps (an amplification step is used to enhance the signal), and any of these three assays can be performed on one of the other channels. The first seven of the cover segments are heated, the temperature of each being controlled by an electronic controller. The first section is heated to 53#{176}C to preheat the tray to incubation temperature before sample is dispensed. All other heater segments are kept at 40#{176}C. The temperature at the heater blanket is controlled to ±1#{176}C.
We measured the temperature in several reaction and detection wells of a tray as it was moving along the track, with water being dispensed in place of reagents. Thermocouples were mounted in three reaction wells and in the porous matrices of three detection wells on the tray. The thermocouple leads were connected to a data logger and were routed in a bundle to allow free movement of the tray. Temperature in the reaction well during the first incubation was 39 ± 1#{176}C; temperature at the wet porous matrix was 37 ± 1#{176}C. The temperature generally dropped <2#{176}C when a reagent or wash solution was added to the pad, but returned to equilibrium again within 2 miii.
Reagent addition:
Reagents are dispensed from bottles via nozzles centered on the reaction well or the detection well; they are pumped with calibrated posi- The system is viewed as an assay factory having an ordered set of pumps, motors, and sensors that can be combined in various configurations. The desired flexibility is achieved by segregating as much assay-specificinformation as possible into configuration files. This information includes sample volume, active operational positions, reagent volumes, number of wash solution pulses, delays between such pulses, and detector output limits. These files are read to determine how to control the six assay channels and the pipettor. A block diagram of the system software architecture is shown in Figure 7 .
The data-reduction software uses assay-specific information so that the raw data from the assay channels can be processed into results. The sample and control data are subjected to numerous limit tests to ensure their validity: minimum and maximum dark counts, control 
Results and Discussion
Accuracy and precision of pipetting: The mean of the weight of 15 replicates of a pipetted sample of bovine serum was calculated for each target volume. CVs <1.6% were obtained for volumes of 60-100 pL. The CV of pipetting volumes >100 zL was <1%.
Detector performance:
The performance of the detector and the integrity of the light seals were checked by using solid plastic scintillators, polyvinyltoluene poly-
Labs., Burbank, CA). The beta-emission excites lowlevel fluorescence from the vinyltoluene polymer. Each scintillator was polymerized in an aluminum cup and fit in the detection well of the disposable reaction tray. The integrated scintillator counts were measured before the start of a run. Three intensities of scintillators were used: 1238, 1912, and 3734 counts/s. The integrated scintillator counts were measured periodically over a period of three weeks; the values for each scintillator varied by 2.5%, 1.0%, and 4.42%, respectively, during that period.
Results of anti -HBc and HBsAg assays: Precision data
for the anti-HBc assay are given in Table 2 . Within-run 
Throughput
The instrument throughput is gated by the pipettor function.
For blood-screening applications (plasma and cell pipetting), 75 samples can be processed per hour to yield 900 test results per hour. However, using the instrument as a six-channel CLIA analyzer (no cell pipetting) cuts the pipettor cycle time to 36 s; this increases the number of samples processed to 150 per hour, to yield up to 900 test results per hour.
Reagents
Coated microparticles, acridinium-labeled conjugates, and transfer and wash solutions were from experimental kits prepared for clinical studies (Abbott Labs., North Chicago, IL) (3) (4) (5) (6) . Anti panel is given in Table 3 . The data were generated by repeating the assay of the sensitivity panel samples, and of several aliquots of the negative control, seven times within a run on both sides A and B of the channel (n = 14). Between-run CV was calculated from three independent runs (n = 42). Within-run and between-run CVs were -5% for samples with concentrations >0.14 pg/L. The mean of the CL signal generated from the negative controls run as samples was 955 counts/6 s(SD We used the CLIA to conduct a clinical study with paid donors' samples from a plasma processing center. Two channels were tested, for HBsAg and anti-HBc, in parallel. The between-run CV of the HBsAg-negative controls was 10.2% (n = 52); for the positive controls, it 1044) . The mean for the negative samples was 12.03 SD below the cutoff for the assay. For the anti-HBc channel, the CV of the CL signal for the negative controls was 6% (n = 56); for the control sample, 9.8% (n = 22); and for the antibody-negative samples, 6.3% (n = 914). We calculated the percentage inhibition and set an assay cutoff at 45% of the inhibition value. The mean for the negative population was 7.34 SD from the assay cutoff.
TSH assay: Figure 8 (top) shows a dose-response curve for the TSH assay. The interpolated concentrations for the low, medium, and high controls are given in Table 5 (r = 0.9983). The limit of detection, calculated by interpolation to the mean zero dose-response signal + 2 SD, is 0.004 milli-int. urnt/L. This value compares well with other CLIA assay results of 0.0 15, obtained by using magnetizable microparticles (7), and 0.005 obtained with coated tubes (8). The assay of TSH is not optimized, and the nonspecific counts at zero analyte concentration may be wash-limited.
In conclusion, we constructed and tested a multichannel heterogeneous chemiluminescence immunoassay system that is free of carryover. The limit for quantifying HBsAg was <0.2 g/L; for anti-HBc, <0.5 PEI units/mL. The negative population was well separated from those with positive results, which decreases the number of borderline results and unnecessary retesting. In a clinical study of HBsAg in a nonselected blood donor population in two blood banks and a plasma processing center, 8964 samples were analyzed with this instrument (6). Seven samples were initially reactive, five of which were reactive in repeat assays; the same five were confirmed positive by neutralization and overnight enzyme immunoassay. Thus, assay specificity was 100%. The mean signal-to-noise ratio for the negative population was separated by 9 SD from the cutoff value of the assay. Although the system is primarily designed to perform high-sensitivity screening assays for blood-banking applications, preliminary data show that analytes requiring wide dynamic range assays such as TSH can also be performed with this system.
